MetaCap

Pelthos Therapeutics (PTHS) vs Genenta Science S.p.A. (SAEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pelthos Therapeutics is the larger company by market cap ($25.1 million vs $24.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PTHS-40.82%SAEN-47.19%
+2%-24%-50%
Nov 3, 20261 yearNov 20, 2026
PTHS-31.84%SAEN-23.70%
+2%-16%-33%
Nov 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PTHS versus SAEN key metrics
MetricPTHSSAEN
Share price$6.38$0.5074
Market cap$25.08M$24.47M
1-day change-8.73%-9.39%
YTD return-79.42%—
1-year return-74.88%—
EPS (TTM)$-23.86$-0.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$16.80M—
Net income (latest FY)$-43.32M—
Gross margin76.25%—
Operating margin-193.09%—
Net margin-257.93%—
52-week high$31.62$2.58
52-week low$6.02$0.50
Distance from 52-week high-79.82%-80.33%
Analyst consensusstrong_buy—
Avg. price target upside+732.92%—
Average volume54.38K85.01K
Shares outstanding3.93M48.22M
Employees929
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Pelthos Therapeutics

PTHS stock →

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

About Genenta Science S.p.A.

SAEN stock →

Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees

PTHS vs SAEN FAQ

Which is bigger, Pelthos Therapeutics or Genenta Science S.p.A.?

Pelthos Therapeutics (PTHS) is larger, with a market capitalization of $25.08M compared with $24.47M for Genenta Science S.p.A. (SAEN).

Are Pelthos Therapeutics and Genenta Science S.p.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons